[Editor Note: This MPEP section is applicable regardless of whether an application is examined under the AIA or under pre-AIA law. For applications subject to the first inventor to file (FITF) provisions of the AIA, the relevant time is \"before the effective filing date of the claimed invention\". For applications subject to pre-AIA 35 U.S.C. 102, the relevant time is \"at the time of the invention\". See MPEP § 2150 et seq. Many of the court decisions discussed in this section involved applications or patents subject to pre-AIA 35 U.S.C. 102. These court decisions may be applicable to applications and patents subject to AIA 35 U.S.C. 102 but the relevant time is before the effective filing date of the claimed invention and not at the time of the invention.]
","rendered_text_plain":"[Editor Note: This MPEP section is applicable regardless of whether an application is examined under the AIA or under pre-AIA law. For applications subject to the first inventor to file (FITF) provisions of the AIA, the relevant time is \"before the effective filing date of the claimed invention\". For applications subject to pre-AIA 35 U.S.C. 102, the relevant time is \"at the time of the invention\". See MPEP § 2150 et seq. Many of the court decisions discussed in this section involved applications or patents subject to pre-AIA 35 U.S.C. 102. These court decisions may be applicable to applications and patents subject to AIA 35 U.S.C. 102 but the relevant time is before the effective filing date of the claimed invention and not at the time of the invention.]","provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d223b3_23296_39d","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx","tags":["editorial_note"]},{"id":"pb_ul55rwdp","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_ul55rwdp","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"The express, implicit, and inherent disclosures of a prior art reference may be relied upon in the rejection of claims under 35 U.S.C. 102 or 103. “The inherent teaching of a prior art reference, a question of fact, arises both in the context of anticipation and obviousness.” In re Napier, 55 F.3d 610, 613, 34 USPQ2d 1782, 1784 (Fed. Cir. 1995) (affirmed a 35 U.S.C. 103 rejection based in part on inherent disclosure in one of the references). See also In re Grasselli, 713 F.2d 731, 739, 218 USPQ 769, 775 (Fed. Cir. 1983).
","rendered_text_plain":"The express, implicit, and inherent disclosures of a prior art reference may be relied upon in the rejection of claims under 35 U.S.C. 102 or 103. “The inherent teaching of a prior art reference, a question of fact, arises both in the context of anticipation and obviousness.” In re Napier, 55 F.3d 610, 613, 34 USPQ2d 1782, 1784 (Fed. Cir. 1995) (affirmed a 35 U.S.C. 103 rejection based in part on inherent disclosure in one of the references). See also In re Grasselli, 713 F.2d 731, 739, 218 USPQ 769, 775 (Fed. Cir. 1983).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_jkyznyop","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_jkyznyop","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY","rendered_text_plain":"I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY","provenance":{"source_file":"s2112.html","source_anchor":"d0e201036/b.0","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_w7xl7xxx","heading_level":2,"heading_text":"I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY"},{"id":"pb_hbehwp7b","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_hbehwp7b","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"“[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer.” Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In In re Crish, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court held that the claimed promoter sequence obtained by sequencing a prior art plasmid that was not previously sequenced was anticipated by the prior art plasmid which necessarily possessed the same DNA sequence as the claimed oligonucleotides. The court stated that “just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel.” Id. See also MPEP § 2112.01 with regard to inherency and product-by-process claims and MPEP § 2141.02 with regard to inherency and rejections under 35 U.S.C. 103.
","rendered_text_plain":"“[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer.” Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In In re Crish, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court held that the claimed promoter sequence obtained by sequencing a prior art plasmid that was not previously sequenced was anticipated by the prior art plasmid which necessarily possessed the same DNA sequence as the claimed oligonucleotides. The court stated that “just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel.” Id. See also MPEP § 2112.01 with regard to inherency and product-by-process claims and MPEP § 2141.02 with regard to inherency and rejections under 35 U.S.C. 103.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_f23vyqdo","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_f23vyqdo","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"II. INHERENT FEATURE NEED NOT BE RECOGNIZED AT THE RELEVANT TIME","rendered_text_plain":"II. INHERENT FEATURE NEED NOT BE RECOGNIZED AT THE RELEVANT TIME","provenance":{"source_file":"s2112.html","source_anchor":"d0e201036/b.2","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_w7xl7xxx","heading_level":2,"heading_text":"II. INHERENT FEATURE NEED NOT BE RECOGNIZED AT THE RELEVANT TIME"},{"id":"pb_zo6lucba","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_zo6lucba","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference. Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003) (rejecting the contention that inherent anticipation requires recognition by a person of ordinary skill in the art before the critical date and allowing expert testimony with respect to post-critical date clinical trials to show inherency); see also Toro Co. v. Deere & Co., 355 F.3d 1313, 1320, 69 USPQ2d 1584, 1590 (Fed. Cir. 2004) (“[T]he fact that a characteristic is a necessary feature or result of a prior-art embodiment (that is itself sufficiently described and enabled) is enough for inherent anticipation, even if that fact was unknown at the time of the prior invention.”); Abbott Labs v. Geneva Pharms., Inc., 182 F.3d 1315, 1319, 51 USPQ2d 1307, 1310 (Fed. Cir. 1999) (“If a product that is offered for sale inherently possesses each of the limitations of the claims, then the invention is on sale, whether or not the parties to the transaction recognize that the product possesses the claimed characteristics.”); Atlas Powder Co. v. IRECO, Inc., 190 F.3d 1342, 1348-49, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999) (“Because ‘sufficient aeration’ was inherent in the prior art, it is irrelevant that the prior art did not recognize the key aspect of [the] invention.... An inherent structure, composition, or function is not necessarily known.”); SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1343-44, 74 USPQ2d 1398, 1406-07 (Fed. Cir. 2005) (holding that a prior art patent to an anhydrous form of a compound “inherently” anticipated the claimed hemihydrate form of the compound because practicing the process in the prior art to manufacture the anhydrous compound “inherently results in at least trace amounts of” the claimed hemihydrate even if the prior art did not discuss or recognize the hemihydrate); In re Omeprazole Patent Litigation, 483 F.3d 1364, 1373, 82 USPQ2d 1643, 1650 (Fed. Cir. 2007) (The court noted that although the inventors may not have recognized that a characteristic of the ingredients in the prior art method resulted in an in situ formation of a separating layer, the in situ formation was nevertheless inherent. “The record shows formation of the in situ separating layer in the prior art even though that process was not recognized at the time. The new realization alone does not render that necessary [sic] prior art patentable.”).
","rendered_text_plain":"There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference. Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003) (rejecting the contention that inherent anticipation requires recognition by a person of ordinary skill in the art before the critical date and allowing expert testimony with respect to post-critical date clinical trials to show inherency); see also Toro Co. v. Deere & Co., 355 F.3d 1313, 1320, 69 USPQ2d 1584, 1590 (Fed. Cir. 2004) (“[T]he fact that a characteristic is a necessary feature or result of a prior-art embodiment (that is itself sufficiently described and enabled) is enough for inherent anticipation, even if that fact was unknown at the time of the prior invention.”); Abbott Labs v. Geneva Pharms., Inc., 182 F.3d 1315, 1319, 51 USPQ2d 1307, 1310 (Fed. Cir. 1999) (“If a product that is offered for sale inherently possesses each of the limitations of the claims, then the invention is on sale, whether or not the parties to the transaction recognize that the product possesses the claimed characteristics.”); Atlas Powder Co. v. IRECO, Inc., 190 F.3d 1342, 1348-49, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999) (“Because ‘sufficient aeration’ was inherent in the prior art, it is irrelevant that the prior art did not recognize the key aspect of [the] invention.... An inherent structure, composition, or function is not necessarily known.”); SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1343-44, 74 USPQ2d 1398, 1406-07 (Fed. Cir. 2005) (holding that a prior art patent to an anhydrous form of a compound “inherently” anticipated the claimed hemihydrate form of the compound because practicing the process in the prior art to manufacture the anhydrous compound “inherently results in at least trace amounts of” the claimed hemihydrate even if the prior art did not discuss or recognize the hemihydrate); In re Omeprazole Patent Litigation, 483 F.3d 1364, 1373, 82 USPQ2d 1643, 1650 (Fed. Cir. 2007) (The court noted that although the inventors may not have recognized that a characteristic of the ingredients in the prior art method resulted in an in situ formation of a separating layer, the in situ formation was nevertheless inherent. “The record shows formation of the in situ separating layer in the prior art even though that process was not recognized at the time. The new realization alone does not render that necessary [sic] prior art patentable.”).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_vdsd6a7m","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_vdsd6a7m","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"III. A REJECTION UNDER 35 U.S.C. 102 AND 103 CAN BE MADE WHEN THE PRIOR ART PRODUCT SEEMS TO BE IDENTICAL EXCEPT THAT THE PRIOR ART IS SILENT AS TO AN INHERENT CHARACTERISTIC","rendered_text_plain":"III. A REJECTION UNDER 35 U.S.C. 102 AND 103 CAN BE MADE WHEN THE PRIOR ART PRODUCT SEEMS TO BE IDENTICAL EXCEPT THAT THE PRIOR ART IS SILENT AS TO AN INHERENT CHARACTERISTIC","provenance":{"source_file":"s2112.html","source_anchor":"d0e201036/b.4","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_w7xl7xxx","heading_level":2,"heading_text":"III. A REJECTION UNDER 35 U.S.C. 102 AND 103 CAN BE MADE WHEN THE PRIOR ART PRODUCT SEEMS TO BE IDENTICAL EXCEPT THAT THE PRIOR ART IS SILENT AS TO AN INHERENT CHARACTERISTIC"},{"id":"pb_4xu2oes4","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_4xu2oes4","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"Where applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103. “There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.” In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102 and 103 rejection is appropriate for these types of claims as well as for composition claims.
","rendered_text_plain":"Where applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103. “There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.” In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102 and 103 rejection is appropriate for these types of claims as well as for composition claims.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201130","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_pkh5qikl","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_pkh5qikl","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"IV. EXAMINER MUST PROVIDE RATIONALE OR EVIDENCE TO SHOW INHERENCY","rendered_text_plain":"IV. EXAMINER MUST PROVIDE RATIONALE OR EVIDENCE TO SHOW INHERENCY","provenance":{"source_file":"s2112.html","source_anchor":"d0e201036/b.6","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_w7xl7xxx","heading_level":2,"heading_text":"IV. EXAMINER MUST PROVIDE RATIONALE OR EVIDENCE TO SHOW INHERENCY"},{"id":"pb_qz3ymp3z","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_qz3ymp3z","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"The fact that a certain result or characteristic may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. In re Rijckaert, 9 F.3d 1531, 1534, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993) (reversed rejection because inherency was based on what would result due to optimization of conditions, not what was necessarily present in the prior art); In re Oelrich, 666 F.2d 578, 581-82, 212 USPQ 323, 326 (CCPA 1981). Also, “[a]n invitation to investigate is not an inherent disclosure” where a prior art reference “discloses no more than a broad genus of potential applications of its discoveries.” Metabolite Labs., Inc. v. Lab.Corp. of Am. Holdings, 370 F.3d 1354, 1367, 71 USPQ2d 1081, 1091 (Fed. Cir. 2004) (explaining that “[a] prior art reference that discloses a genus still does not inherently disclose all species within that broad category” but must be examined to see if a disclosure of the claimed species has been made or whether the prior art reference merely invites further experimentation to find the species).
","rendered_text_plain":"The fact that a certain result or characteristic may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. In re Rijckaert, 9 F.3d 1531, 1534, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993) (reversed rejection because inherency was based on what would result due to optimization of conditions, not what was necessarily present in the prior art); In re Oelrich, 666 F.2d 578, 581-82, 212 USPQ 323, 326 (CCPA 1981). Also, “[a]n invitation to investigate is not an inherent disclosure” where a prior art reference “discloses no more than a broad genus of potential applications of its discoveries.” Metabolite Labs., Inc. v. Lab.Corp. of Am. Holdings, 370 F.3d 1354, 1367, 71 USPQ2d 1081, 1091 (Fed. Cir. 2004) (explaining that “[a] prior art reference that discloses a genus still does not inherently disclose all species within that broad category” but must be examined to see if a disclosure of the claimed species has been made or whether the prior art reference merely invites further experimentation to find the species).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201164","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_ohiigq4r","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_ohiigq4r","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"“In relying upon the theory of inherency, the examiner must provide a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art.” Ex parte Levy, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990) (emphasis in original). In PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc., 773 F.3d 1186, 112 USPQ2d 1945 (Fed. Cir. 2014), the Federal Circuit remanded a decision to the district court because the record did not present sufficient evidence to prove inherency in the context of obviousness. The district court concluded the pharmacokinetic parameters of a claim are inherent properties of the obvious formulation. The Federal Circuit stated that while “inherency may support a missing claim limitation in an obviousness analysis”, “the use of inherency, a doctrine originally rooted in anticipation, must be carefully circumscribed in the context of obviousness.” Id. at 1194-95, 112 USPQ2d at 1952. “[I]n order to rely on inherency to establish the existence of a claim limitation in the prior art in an obviousness analysis – the limitation at issue necessarily must be present, or the natural result of the combination of elements explicitly disclosed by the prior art.” Id. at 1195-96, 112 USPQ2d at 1952. But see, Persion Pharms. LLC v. Alvogen Malta Operations LTD., 945 F.3d 1184, 1191, 2019 USPQ2d 494084 (Fed. Cir. 2019), where the court stated that a proper finding of inherency does not require that all limitations are taught in a single reference, and that inherency may meet a missing claim limitation when the limitation is “the natural result of the combination of prior art elements.” (emphasis in original). The court found that pharmacokinetic limitations of the asserted claims were inherently met by combining prior art references because the limitations were necessarily present in the prior art combination. Id. See also Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 1329-32, 2020 USPQ2d 6227 (Fed. Cir. 2020).
","rendered_text_plain":"“In relying upon the theory of inherency, the examiner must provide a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art.” Ex parte Levy, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990) (emphasis in original). In PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc., 773 F.3d 1186, 112 USPQ2d 1945 (Fed. Cir. 2014), the Federal Circuit remanded a decision to the district court because the record did not present sufficient evidence to prove inherency in the context of obviousness. The district court concluded the pharmacokinetic parameters of a claim are inherent properties of the obvious formulation. The Federal Circuit stated that while “inherency may support a missing claim limitation in an obviousness analysis”, “the use of inherency, a doctrine originally rooted in anticipation, must be carefully circumscribed in the context of obviousness.” Id. at 1194-95, 112 USPQ2d at 1952. “[I]n order to rely on inherency to establish the existence of a claim limitation in the prior art in an obviousness analysis – the limitation at issue necessarily must be present, or the natural result of the combination of elements explicitly disclosed by the prior art.” Id. at 1195-96, 112 USPQ2d at 1952. But see, Persion Pharms. LLC v. Alvogen Malta Operations LTD., 945 F.3d 1184, 1191, 2019 USPQ2d 494084 (Fed. Cir. 2019), where the court stated that a proper finding of inherency does not require that all limitations are taught in a single reference, and that inherency may meet a missing claim limitation when the limitation is “the natural result of the combination of prior art elements.” (emphasis in original). The court found that pharmacokinetic limitations of the asserted claims were inherently met by combining prior art references because the limitations were necessarily present in the prior art combination. Id. See also Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 1329-32, 2020 USPQ2d 6227 (Fed. Cir. 2020).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201188","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_hfcu5s4r","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_hfcu5s4r","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"In In re Schreiber, 128 F.3d 1473, 44 USPQ2d 1429 (Fed. Cir. 1997), the court affirmed a finding that a prior patent to a conical spout used primarily to dispense oil from an oil can inherently performed the functions recited in applicant’s claim to a conical container top for dispensing popped popcorn. The examiner had asserted inherency based on the structural similarity between the patented spout and applicant’s disclosed top, i.e., both structures had the same general shape. The court stated:
","rendered_text_plain":"In In re Schreiber, 128 F.3d 1473, 44 USPQ2d 1429 (Fed. Cir. 1997), the court affirmed a finding that a prior patent to a conical spout used primarily to dispense oil from an oil can inherently performed the functions recited in applicant’s claim to a conical container top for dispensing popped popcorn. The examiner had asserted inherency based on the structural similarity between the patented spout and applicant’s disclosed top, i.e., both structures had the same general shape. The court stated:","provenance":{"source_file":"s2112.html","source_anchor":"d0e201203","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_46ee3qbz","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_46ee3qbz","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"V. ONCE A REFERENCE TEACHING PRODUCT APPEARING TO BE SUBSTANTIALLY IDENTICAL IS MADE THE BASIS OF A REJECTION, AND THE EXAMINER PRESENTS EVIDENCE OR REASONING TO SHOW INHERENCY, THE BURDEN OF PRODUCTION SHIFTS TO THE APPLICANT","rendered_text_plain":"V. ONCE A REFERENCE TEACHING PRODUCT APPEARING TO BE SUBSTANTIALLY IDENTICAL IS MADE THE BASIS OF A REJECTION, AND THE EXAMINER PRESENTS EVIDENCE OR REASONING TO SHOW INHERENCY, THE BURDEN OF PRODUCTION SHIFTS TO THE APPLICANT","provenance":{"source_file":"s2112.html","source_anchor":"d0e201036/b.8","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_w7xl7xxx","heading_level":2,"heading_text":"V. ONCE A REFERENCE TEACHING PRODUCT APPEARING TO BE SUBSTANTIALLY IDENTICAL IS MADE THE BASIS OF A REJECTION, AND THE EXAMINER PRESENTS EVIDENCE OR REASONING TO SHOW INHERENCY, THE BURDEN OF PRODUCTION SHIFTS TO THE APPLICANT"},{"id":"pb_kukynnj6","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_kukynnj6","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"“[T]he PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on ‘inherency’ under 35 U.S.C. 102, on ‘prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same.” In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977) (footnote and citation omitted). The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (citing Best, 562 F.2d at 1255).
","rendered_text_plain":"“[T]he PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on ‘inherency’ under 35 U.S.C. 102, on ‘prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same.” In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977) (footnote and citation omitted). The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (citing Best, 562 F.2d at 1255).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201222","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_3imzasht","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_3imzasht","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"In Fitzgerald, the claims were directed to a self-locking screw-threaded fastener comprising a metallic threaded fastener having patches of crystallizable thermoplastic bonded thereto. The claim further specified that the thermoplastic had a reduced degree of crystallization shrinkage. The specification disclosed that the locking fastener was made by heating the metal fastener to melt a thermoplastic blank which is pressed against the metal. After the thermoplastic adheres to the metal fastener, the end product is cooled by quenching in water. The examiner made a rejection based on a U.S. patent to Barnes. Barnes taught a self-locking fastener in which the patch of thermoplastic was made by depositing thermoplastic powder on a metallic fastener which was then heated. The end product was cooled in ambient air, by cooling air or by contacting the fastener with a water trough. The court first noted that the two fasteners were identical or only slightly different from each other. “Both fasteners possess the same utility, employ the same crystallizable polymer (nylon 11), and have an adherent plastic patch formed by melting and then cooling the polymer.” Id. at 596 n.1, 619 F.2d at 70 n.1. The court then noted that the Board had found that Barnes’ cooling rate could reasonably be expected to result in a polymer possessing the claimed crystallization shrinkage rate. Applicants had not rebutted this finding with evidence that the shrinkage rate was indeed different. They had only argued that the crystallization shrinkage rate was dependent on the cool down rate and that the cool down rate of Barnes was much slower than theirs. Because a difference in the cool down rate does not necessarily result in a difference in shrinkage, objective evidence was required to rebut the 35 U.S.C. 102/103prima facie case.
","rendered_text_plain":"In Fitzgerald, the claims were directed to a self-locking screw-threaded fastener comprising a metallic threaded fastener having patches of crystallizable thermoplastic bonded thereto. The claim further specified that the thermoplastic had a reduced degree of crystallization shrinkage. The specification disclosed that the locking fastener was made by heating the metal fastener to melt a thermoplastic blank which is pressed against the metal. After the thermoplastic adheres to the metal fastener, the end product is cooled by quenching in water. The examiner made a rejection based on a U.S. patent to Barnes. Barnes taught a self-locking fastener in which the patch of thermoplastic was made by depositing thermoplastic powder on a metallic fastener which was then heated. The end product was cooled in ambient air, by cooling air or by contacting the fastener with a water trough. The court first noted that the two fasteners were identical or only slightly different from each other. “Both fasteners possess the same utility, employ the same crystallizable polymer (nylon 11), and have an adherent plastic patch formed by melting and then cooling the polymer.” Id. at 596 n.1, 619 F.2d at 70 n.1. The court then noted that the Board had found that Barnes’ cooling rate could reasonably be expected to result in a polymer possessing the claimed crystallization shrinkage rate. Applicants had not rebutted this finding with evidence that the shrinkage rate was indeed different. They had only argued that the crystallization shrinkage rate was dependent on the cool down rate and that the cool down rate of Barnes was much slower than theirs. Because a difference in the cool down rate does not necessarily result in a difference in shrinkage, objective evidence was required to rebut the 35 U.S.C. 102/103prima facie case.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201240","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_5rqxbgj7","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_5rqxbgj7","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"In Schreiber, 128 F.3d 1473, 1478, 44 USPQ2d 1429, 1432 (Fed.Cir.1997), the court held that applicant’s declaration failed to overcome a prima facie case of anticipation because the declaration did not specify the dimensions of either the dispensing top that was tested or the popcorn that was used. Applicant’s declaration merely asserted that a conical dispensing top built according to a figure in the prior art patent was too small to jam and dispense popcorn and thus could not inherently perform the functions recited in applicant’s claims. The court pointed out the disclosure of the prior art patent was not limited to use as an oil can dispenser, but rather was broader than the precise configuration shown in the patent’s figure. The court also noted that the Board found as a factual matter that a scaled-up version of the top disclosed in the patent would be capable of performing the functions recited in applicant’s claim.
","rendered_text_plain":"In Schreiber, 128 F.3d 1473, 1478, 44 USPQ2d 1429, 1432 (Fed.Cir.1997), the court held that applicant’s declaration failed to overcome a prima facie case of anticipation because the declaration did not specify the dimensions of either the dispensing top that was tested or the popcorn that was used. Applicant’s declaration merely asserted that a conical dispensing top built according to a figure in the prior art patent was too small to jam and dispense popcorn and thus could not inherently perform the functions recited in applicant’s claims. The court pointed out the disclosure of the prior art patent was not limited to use as an oil can dispenser, but rather was broader than the precise configuration shown in the patent’s figure. The court also noted that the Board found as a factual matter that a scaled-up version of the top disclosed in the patent would be capable of performing the functions recited in applicant’s claim.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201258","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"pb_sbbzbov5","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_sbbzbov5","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"See MPEP § 2113 for more information on the analogous burden of proof applied to product-by-process claims.
","rendered_text_plain":"See MPEP § 2113 for more information on the analogous burden of proof applied to product-by-process claims.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201267","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"cs_bcvvwgih","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_bcvvwgih","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Schreiber, 128 F.3d 1473, 44 USPQ2d 1429 (Fed. Cir. 1997)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Schreiber","all_citations":["128 F.3d 1473","44 USPQ2d 1429"],"canonical_citation":"In re Schreiber, 128 F.3d 1473, 44 USPQ2d 1429 (Fed. Cir. 1997)","decision_year":1997,"court":"Fed. Cir."},{"id":"nq_l2pbudhk","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/nq_l2pbudhk","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"narrative_quote","rendered_text_html":"","rendered_text_plain":"[N]othing in Schreiber’s [applicant’s] claim suggests that Schreiber’s container is 'of a different shape’ than Harz’s [patent]. In fact, [ ] an embodiment according to Harz (Fig. 5) and the embodiment depicted in figure 1 of Schreiber’s application have the same general shape. For that reason, the examiner was justified in concluding that the opening of a conically shaped top as disclosed by Harz is inherently of a size sufficient to ‘allow [ ] several kernels of popped popcorn to pass through at the same time’ and that the taper of Harz’s conically shaped top is inherently of such a shape ‘as to by itself jam up the popped popcorn before the end of the cone and permit the dispensing of only a few kernels at a shake of a package when the top is mounted to the container.’ The examiner therefore correctly found that Harz established a prima facie case of anticipation.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201209","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"source_anchor":"d0e201209","host_section_id":"se_w7xl7xxx","source_case_id":"cs_bcvvwgih"},{"id":"pb_nvvyx6qy","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_nvvyx6qy","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"[N]othing in Schreiber’s [applicant’s] claim suggests that Schreiber’s container is 'of a different shape’ than Harz’s [patent]. In fact, [ ] an embodiment according to Harz (Fig. 5) and the embodiment depicted in figure 1 of Schreiber’s application have the same general shape. For that reason, the examiner was justified in concluding that the opening of a conically shaped top as disclosed by Harz is inherently of a size sufficient to ‘allow [ ] several kernels of popped popcorn to pass through at the same time’ and that the taper of Harz’s conically shaped top is inherently of such a shape ‘as to by itself jam up the popped popcorn before the end of the cone and permit the dispensing of only a few kernels at a shake of a package when the top is mounted to the container.’ The examiner therefore correctly found that Harz established a prima facie case of anticipation.
Schreiber, 128 F.3d at 1478, 44 USPQ2d at 1432.
","rendered_text_plain":"Schreiber, 128 F.3d at 1478, 44 USPQ2d at 1432.","provenance":{"source_file":"s2112.html","source_anchor":"d0e201213","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_w7xl7xxx"},{"id":"se_7hgbpjeu","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/se_7hgbpjeu","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"section","rendered_text_html":"","rendered_text_plain":"","provenance":{"source_file":"s2112.html","source_anchor":"d0e201273","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"akn_urn":"/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2112_01","canonical_url":"https://mpep.io/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2112_01","section_number":"2112.01","chapter":"2100","depth":1,"title":"Composition, Product, and Apparatus Claims","revision_tag":"R-10.2019","children_ids":["pb_rtyenzkq","pb_yj3sbauc","pb_5gnvmizp","pb_4im6yiow","pb_zjsijpps","pb_5w4xofrn","pb_tlhvxuyc","pb_kxzigdpz"],"parent_section_id":"se_w7xl7xxx"},{"id":"pb_rtyenzkq","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_rtyenzkq","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"I. PRODUCT AND APPARATUS CLAIMS — WHEN THE STRUCTURE RECITED IN THE REFERENCE IS SUBSTANTIALLY IDENTICAL TO THAT OF THE CLAIMS, CLAIMED PROPERTIES OR FUNCTIONS ARE PRESUMED TO BE INHERENT","rendered_text_plain":"I. PRODUCT AND APPARATUS CLAIMS — WHEN THE STRUCTURE RECITED IN THE REFERENCE IS SUBSTANTIALLY IDENTICAL TO THAT OF THE CLAIMS, CLAIMED PROPERTIES OR FUNCTIONS ARE PRESUMED TO BE INHERENT","provenance":{"source_file":"s2112.html","source_anchor":"d0e201273/b.0","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_7hgbpjeu","heading_level":2,"heading_text":"I. PRODUCT AND APPARATUS CLAIMS — WHEN THE STRUCTURE RECITED IN THE REFERENCE IS SUBSTANTIALLY IDENTICAL TO THAT OF THE CLAIMS, CLAIMED PROPERTIES OR FUNCTIONS ARE PRESUMED TO BE INHERENT"},{"id":"pb_yj3sbauc","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_yj3sbauc","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). “When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. See also Titanium Metals Corp.v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) (Claims were directed to a titanium alloy containing 0.2-0.4% Mo and 0.6-0.9% Ni having corrosion resistance. A Russian article disclosed a titanium alloy containing 0.25% Mo and 0.75% Ni but was silent as to corrosion resistance. The Federal Circuit held that the claim was anticipated because the percentages of Mo and Ni were squarely within the claimed ranges. The court went on to say that it was immaterial what properties the alloys had or who discovered the properties because the composition is the same and thus must necessarily exhibit the properties.).
","rendered_text_plain":"Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). “When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. See also Titanium Metals Corp.v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) (Claims were directed to a titanium alloy containing 0.2-0.4% Mo and 0.6-0.9% Ni having corrosion resistance. A Russian article disclosed a titanium alloy containing 0.25% Mo and 0.75% Ni but was silent as to corrosion resistance. The Federal Circuit held that the claim was anticipated because the percentages of Mo and Ni were squarely within the claimed ranges. The court went on to say that it was immaterial what properties the alloys had or who discovered the properties because the composition is the same and thus must necessarily exhibit the properties.).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201281","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_7hgbpjeu"},{"id":"pb_5gnvmizp","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_5gnvmizp","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"See also In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971) (Claim 1 was directed to a parachute canopy having concentric circumferential panels radially separated from each other by radially extending tie lines. The panels were separated “such that the critical velocity of each successively larger panel will be less than the critical velocity of the previous panel, whereby said parachute will sequentially open and thus gradually decelerate.” The court found that the claim was anticipated by Menget. Menget taught a parachute having three circumferential panels separated by tie lines. The court upheld the rejection finding that applicant had failed to show that Menget did not possess the functional characteristics of the claims.); Northam Warren Corp.v.D. F. Newfield Co., 7 F.Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934) (A patent to a pencil for cleaning fingernails was held invalid because a pencil of the same structure for writing was found in the prior art.).
","rendered_text_plain":"See also In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971) (Claim 1 was directed to a parachute canopy having concentric circumferential panels radially separated from each other by radially extending tie lines. The panels were separated “such that the critical velocity of each successively larger panel will be less than the critical velocity of the previous panel, whereby said parachute will sequentially open and thus gradually decelerate.” The court found that the claim was anticipated by Menget. Menget taught a parachute having three circumferential panels separated by tie lines. The court upheld the rejection finding that applicant had failed to show that Menget did not possess the functional characteristics of the claims.); Northam Warren Corp.v.D. F. Newfield Co., 7 F.Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934) (A patent to a pencil for cleaning fingernails was held invalid because a pencil of the same structure for writing was found in the prior art.).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201308","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_7hgbpjeu"},{"id":"pb_4im6yiow","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_4im6yiow","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"II. COMPOSITION CLAIMS — IF THE COMPOSITION IS PHYSICALLY THE SAME, IT MUST HAVE THE SAME PROPERTIES","rendered_text_plain":"II. COMPOSITION CLAIMS — IF THE COMPOSITION IS PHYSICALLY THE SAME, IT MUST HAVE THE SAME PROPERTIES","provenance":{"source_file":"s2112.html","source_anchor":"d0e201273/b.2","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_7hgbpjeu","heading_level":2,"heading_text":"II. COMPOSITION CLAIMS — IF THE COMPOSITION IS PHYSICALLY THE SAME, IT MUST HAVE THE SAME PROPERTIES"},{"id":"pb_zjsijpps","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_zjsijpps","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"“Products of identical chemical composition can not have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id. (Applicant argued that the claimed composition was a pressure sensitive adhesive containing a tacky polymer while the product of the reference was hard and abrasion resistant. “The Board correctly found that the virtual identity of monomers and procedures sufficed to support a prima facie case of unpatentability of Spada’s polymer latexes for lack of novelty.”).
","rendered_text_plain":"“Products of identical chemical composition can not have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id. (Applicant argued that the claimed composition was a pressure sensitive adhesive containing a tacky polymer while the product of the reference was hard and abrasion resistant. “The Board correctly found that the virtual identity of monomers and procedures sufficed to support a prima facie case of unpatentability of Spada’s polymer latexes for lack of novelty.”).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201330","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_7hgbpjeu"},{"id":"pb_5w4xofrn","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_5w4xofrn","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"III. PRODUCT CLAIMS – NONFUNCTIONAL PRINTED MATTER DOES NOT DISTINGUISH CLAIMED PRODUCT FROM OTHERWISE IDENTICAL PRIOR ART PRODUCT","rendered_text_plain":"III. PRODUCT CLAIMS – NONFUNCTIONAL PRINTED MATTER DOES NOT DISTINGUISH CLAIMED PRODUCT FROM OTHERWISE IDENTICAL PRIOR ART PRODUCT","provenance":{"source_file":"s2112.html","source_anchor":"d0e201273/b.4","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_7hgbpjeu","heading_level":2,"heading_text":"III. PRODUCT CLAIMS – NONFUNCTIONAL PRINTED MATTER DOES NOT DISTINGUISH CLAIMED PRODUCT FROM OTHERWISE IDENTICAL PRIOR ART PRODUCT"},{"id":"pb_tlhvxuyc","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_tlhvxuyc","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) (Claim at issue was a kit requiring instructions and a buffer agent. The Federal Circuit held that the claim was anticipated by a prior art reference that taught a kit that included instructions and a buffer agent, even though the content of the instructions differed, explaining “[i]f we were to adopt [applicant’s] position, anyone could continue patenting a product indefinitely provided that they add a new instruction sheet to the product.”). See also In re Gulack, 703 F.2d 1381, 1385-86, 217 USPQ 401, 404 (Fed. Cir. 1983) ( \"Where the printed matter is not functionally related to the substrate, the printed matter will not distinguish the invention from the prior art in terms of patentability….[T]he critical question is whether there exists any new and unobvious functional relationship between the printed matter and the substrate.\" ); In re Miller, 418 F.2d 1392, 1396 (CCPA 1969) (finding a new and nonobvious relationship between a measuring cup and writing showing how to “half” a recipe); In re Seid, 161 F.2d 229, 73 USPQ 431 (CCPA 1947) (matters relating to ornamentation only which have no mechanical function cannot be relied upon to patentably distinguish the claimed invention from the prior art); In re Xiao, 462 Fed. App'x 947, 950-51 (Fed. Cir. 2011) (non-precedential) (affirming an obviousness rejection of claims directed to a tumbler lock that used letters instead of numbers and had a wild-card label instead of one of the letters); In re Bryan, 323 Fed. App'x 898, 901 (Fed. Cir. 2009) (non-precedential) (printed matter on game cards bears no new and nonobvious functional relationship to game board).
","rendered_text_plain":"Where the only difference between a prior art product and a claimed product is printed matter that is not functionally related to the product, the content of the printed matter will not distinguish the claimed product from the prior art. In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004) (Claim at issue was a kit requiring instructions and a buffer agent. The Federal Circuit held that the claim was anticipated by a prior art reference that taught a kit that included instructions and a buffer agent, even though the content of the instructions differed, explaining “[i]f we were to adopt [applicant’s] position, anyone could continue patenting a product indefinitely provided that they add a new instruction sheet to the product.”). See also In re Gulack, 703 F.2d 1381, 1385-86, 217 USPQ 401, 404 (Fed. Cir. 1983) ( \"Where the printed matter is not functionally related to the substrate, the printed matter will not distinguish the invention from the prior art in terms of patentability….[T]he critical question is whether there exists any new and unobvious functional relationship between the printed matter and the substrate.\" ); In re Miller, 418 F.2d 1392, 1396 (CCPA 1969) (finding a new and nonobvious relationship between a measuring cup and writing showing how to “half” a recipe); In re Seid, 161 F.2d 229, 73 USPQ 431 (CCPA 1947) (matters relating to ornamentation only which have no mechanical function cannot be relied upon to patentably distinguish the claimed invention from the prior art); In re Xiao, 462 Fed. App'x 947, 950-51 (Fed. Cir. 2011) (non-precedential) (affirming an obviousness rejection of claims directed to a tumbler lock that used letters instead of numbers and had a wild-card label instead of one of the letters); In re Bryan, 323 Fed. App'x 898, 901 (Fed. Cir. 2009) (non-precedential) (printed matter on game cards bears no new and nonobvious functional relationship to game board).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_7hgbpjeu"},{"id":"pb_kxzigdpz","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_kxzigdpz","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"The court has extended the rationale in the printed matter cases, in which, for example, written instructions are added to a known product, to method claims in which \"an instruction limitation\" (i.e., a limitation “informing” someone about the existence of an inherent property of that method) is added to a method known in the art. King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1279, 95 USPQ2d 1833, 1842 (2010). Similar to the inquiry for products with printed matter thereon, for such method cases the relevant inquiry is whether a new and nonobvious functional relationship with the known method exists. In King Pharma, the court found that the relevant determination is whether the \"instruction limitation\" has a \"new and unobvious functional relationship\" with the known method of administering the drug with food. Id. The court held that the relationship was non-functional because \"[i]nforming a patient about the benefits of a drug in no way transforms the process of taking the drug with food.\" Id. That is, the actual method of taking a drug with food is the same regardless of whether the patient is informed of the benefits. Id. “In other words, the ‘informing’ limitation ‘in no way depends on the method, and the method does not depend on the ‘informing’ limitation.’\" Id. (citing In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004)); see also In re Kao, 639 F.3d 1057, 1072-73, 98 USPQ2d 1799, 1811-12 (Fed. Cir. 2011).
","rendered_text_plain":"The court has extended the rationale in the printed matter cases, in which, for example, written instructions are added to a known product, to method claims in which \"an instruction limitation\" (i.e., a limitation “informing” someone about the existence of an inherent property of that method) is added to a method known in the art. King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1279, 95 USPQ2d 1833, 1842 (2010). Similar to the inquiry for products with printed matter thereon, for such method cases the relevant inquiry is whether a new and nonobvious functional relationship with the known method exists. In King Pharma, the court found that the relevant determination is whether the \"instruction limitation\" has a \"new and unobvious functional relationship\" with the known method of administering the drug with food. Id. The court held that the relationship was non-functional because \"[i]nforming a patient about the benefits of a drug in no way transforms the process of taking the drug with food.\" Id. That is, the actual method of taking a drug with food is the same regardless of whether the patient is informed of the benefits. Id. “In other words, the ‘informing’ limitation ‘in no way depends on the method, and the method does not depend on the ‘informing’ limitation.’\" Id. (citing In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004)); see also In re Kao, 639 F.3d 1057, 1072-73, 98 USPQ2d 1799, 1811-12 (Fed. Cir. 2011).","provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d24d26_27ff5_327","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_7hgbpjeu"},{"id":"se_podrfx5d","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/se_podrfx5d","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"section","rendered_text_html":"","rendered_text_plain":"","provenance":{"source_file":"s2112.html","source_anchor":"d0e201360","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"akn_urn":"/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2112_02","canonical_url":"https://mpep.io/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2112_02","section_number":"2112.02","chapter":"2100","depth":1,"title":"Process Claims","revision_tag":"R-01.2024","children_ids":["pb_kyssoqiq","pb_2nihdymr","pb_cxdgp2f3","pb_y34bvfxf"],"parent_section_id":"se_w7xl7xxx"},{"id":"pb_kyssoqiq","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_kyssoqiq","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"I. PROCESS CLAIMS — PRIOR ART DEVICE ANTICIPATES A CLAIMED PROCESS IF THE DEVICE CARRIES OUT THE PROCESS DURING NORMAL OPERATION","rendered_text_plain":"I. PROCESS CLAIMS — PRIOR ART DEVICE ANTICIPATES A CLAIMED PROCESS IF THE DEVICE CARRIES OUT THE PROCESS DURING NORMAL OPERATION","provenance":{"source_file":"s2112.html","source_anchor":"d0e201360/b.0","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_podrfx5d","heading_level":2,"heading_text":"I. PROCESS CLAIMS — PRIOR ART DEVICE ANTICIPATES A CLAIMED PROCESS IF THE DEVICE CARRIES OUT THE PROCESS DURING NORMAL OPERATION"},{"id":"pb_2nihdymr","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_2nihdymr","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"Under the principles of inherency, if a prior art device, in its normal and usual operation, would necessarily perform the method claimed, then the method claimed will be considered to be anticipated by the prior art device. When the prior art device is the same as a device described in the specification for carrying out the claimed method, it can be assumed the device will inherently perform the claimed process. In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 1986) (The claims were directed to a method of enhancing color effects produced by ambient light through a process of absorption and reflection of the light off a coated substrate. A prior art reference to Donley disclosed a glass substrate coated with silver and metal oxide 200-800 angstroms thick. While Donley disclosed using the coated substrate to produce architectural colors, the absorption and reflection mechanisms of the claimed process were not disclosed. However, King’s specification disclosed using a coated substrate of Donley’s structure for use in his process. The Federal Circuit upheld the Board’s finding that “Donley inherently performs the function disclosed in the method claims on appeal when that device is used in ‘normal and usual operation’” and found that a prima facie case of anticipation was made out. Id. at 138, 801 F.2d at 1326. It was up to applicant to prove that Donley’s structure would not perform the claimed method when placed in ambient light.). See also In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977) (Applicant claimed a process for preparing a hydrolytically-stable zeolitic aluminosilicate which included a step of “cooling the steam zeolite ... at a rate sufficiently rapid that the cooled zeolite exhibits an X-ray diffraction pattern ....” All the process limitations were expressly disclosed by a U.S. patent to Hansford except the cooling step. The court stated that any sample of Hansford’s zeolite would necessarily be cooled to facilitate subsequent handling. Therefore, rejections under 35 U.S.C. 102 and 103 were properly made. Applicant had failed to introduce any evidence comparing X-ray diffraction patterns showing a difference in cooling rate between the claimed process and that of Hansford or any data showing that the process of Hansford would result in a product with a different X-ray diffraction. Either type of evidence would have rebutted the rejections under 35 U.S.C. 102. A further analysis would be necessary to determine if the process was nonobvious under 35 U.S.C. 103.); Ex parteNovitski, 26 USPQ2d 1389 (Bd. Pat. App. & Inter. 1993) (The Board rejected a claim directed to a method for protecting a plant from plant pathogenic nematodes by inoculating the plant with a nematode inhibiting strain of P. cepacia. A U.S. patent to Dart disclosed inoculation using P. cepacia type Wisconsin 526 bacteria for protecting the plant from fungal disease. Dart was silent as to nematode inhibition but the Board concluded that nematode inhibition was an inherent property of the bacteria. The Board noted that applicant had stated in the specification that Wisconsin 526 possesses an 18% nematode inhibition rating.).
","rendered_text_plain":"Under the principles of inherency, if a prior art device, in its normal and usual operation, would necessarily perform the method claimed, then the method claimed will be considered to be anticipated by the prior art device. When the prior art device is the same as a device described in the specification for carrying out the claimed method, it can be assumed the device will inherently perform the claimed process. In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 1986) (The claims were directed to a method of enhancing color effects produced by ambient light through a process of absorption and reflection of the light off a coated substrate. A prior art reference to Donley disclosed a glass substrate coated with silver and metal oxide 200-800 angstroms thick. While Donley disclosed using the coated substrate to produce architectural colors, the absorption and reflection mechanisms of the claimed process were not disclosed. However, King’s specification disclosed using a coated substrate of Donley’s structure for use in his process. The Federal Circuit upheld the Board’s finding that “Donley inherently performs the function disclosed in the method claims on appeal when that device is used in ‘normal and usual operation’” and found that a prima facie case of anticipation was made out. Id. at 138, 801 F.2d at 1326. It was up to applicant to prove that Donley’s structure would not perform the claimed method when placed in ambient light.). See also In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977) (Applicant claimed a process for preparing a hydrolytically-stable zeolitic aluminosilicate which included a step of “cooling the steam zeolite ... at a rate sufficiently rapid that the cooled zeolite exhibits an X-ray diffraction pattern ....” All the process limitations were expressly disclosed by a U.S. patent to Hansford except the cooling step. The court stated that any sample of Hansford’s zeolite would necessarily be cooled to facilitate subsequent handling. Therefore, rejections under 35 U.S.C. 102 and 103 were properly made. Applicant had failed to introduce any evidence comparing X-ray diffraction patterns showing a difference in cooling rate between the claimed process and that of Hansford or any data showing that the process of Hansford would result in a product with a different X-ray diffraction. Either type of evidence would have rebutted the rejections under 35 U.S.C. 102. A further analysis would be necessary to determine if the process was nonobvious under 35 U.S.C. 103.); Ex parteNovitski, 26 USPQ2d 1389 (Bd. Pat. App. & Inter. 1993) (The Board rejected a claim directed to a method for protecting a plant from plant pathogenic nematodes by inoculating the plant with a nematode inhibiting strain of P. cepacia. A U.S. patent to Dart disclosed inoculation using P. cepacia type Wisconsin 526 bacteria for protecting the plant from fungal disease. Dart was silent as to nematode inhibition but the Board concluded that nematode inhibition was an inherent property of the bacteria. The Board noted that applicant had stated in the specification that Wisconsin 526 possesses an 18% nematode inhibition rating.).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_podrfx5d"},{"id":"pb_cxdgp2f3","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_cxdgp2f3","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"II. PROCESS OF USE CLAIMS — NEW AND NONOBVIOUS USES OF OLD STRUCTURES AND COMPOSITIONS MAY BE PATENTABLE","rendered_text_plain":"II. PROCESS OF USE CLAIMS — NEW AND NONOBVIOUS USES OF OLD STRUCTURES AND COMPOSITIONS MAY BE PATENTABLE","provenance":{"source_file":"s2112.html","source_anchor":"d0e201360/b.2","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"informal_heading","host_section_id":"se_podrfx5d","heading_level":2,"heading_text":"II. PROCESS OF USE CLAIMS — NEW AND NONOBVIOUS USES OF OLD STRUCTURES AND COMPOSITIONS MAY BE PATENTABLE"},{"id":"pb_y34bvfxf","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/pb_y34bvfxf","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"prose_block","rendered_text_html":"The discovery of a new use for an old structure based on unknown properties of the structure might be patentable to the discoverer as a process of using. In re Hack, 245 F.2d 246, 248, 114 USPQ 161, 163 (CCPA 1957). However, when the claim recites using an old composition or structure and the “use” is directed to a result or property of that composition or structure, then the claim is anticipated. In reMay, 574 F.2d 1082, 1090, 197 USPQ 601, 607 (CCPA 1978) (Claims 1 and 6, directed to a method of effecting nonaddictive analgesia (pain reduction) in animals, were found to be anticipated by the applied prior art which disclosed the same compounds, as well as a method of using them for effecting analgesia but which was silent as to addiction. The court upheld the rejection and stated that the inventors had merely found a new property of the compound and such a discovery did not constitute a new use. The court went on to reverse the obviousness rejection of claims 2-5 and 7-10 which recited a process of using a new compound. The court relied on evidence showing that the nonaddictive property of the new compound was unexpected.). See also In re Tomlinson, 363 F.2d 928, 150 USPQ 623 (CCPA 1966) (The claim was directed to a process of inhibiting light degradation of polypropylene by mixing it with one of a genus of compounds, including nickel dithiocarbamate. A reference taught mixing polypropylene with nickel dithiocarbamate to lower heat degradation. The court held that the claims read on the obvious process of mixing polypropylene with the nickel dithiocarbamate and that the preamble of the claim was merely directed to the result of mixing the two materials. “While the references do not show a specific recognition of that result, its discovery by appellants is tantamount only to finding a property in the old composition.” 363 F.2d at 934, 150 USPQ at 628 (emphasis in original)).
","rendered_text_plain":"The discovery of a new use for an old structure based on unknown properties of the structure might be patentable to the discoverer as a process of using. In re Hack, 245 F.2d 246, 248, 114 USPQ 161, 163 (CCPA 1957). However, when the claim recites using an old composition or structure and the “use” is directed to a result or property of that composition or structure, then the claim is anticipated. In reMay, 574 F.2d 1082, 1090, 197 USPQ 601, 607 (CCPA 1978) (Claims 1 and 6, directed to a method of effecting nonaddictive analgesia (pain reduction) in animals, were found to be anticipated by the applied prior art which disclosed the same compounds, as well as a method of using them for effecting analgesia but which was silent as to addiction. The court upheld the rejection and stated that the inventors had merely found a new property of the compound and such a discovery did not constitute a new use. The court went on to reverse the obviousness rejection of claims 2-5 and 7-10 which recited a process of using a new compound. The court relied on evidence showing that the nonaddictive property of the new compound was unexpected.). See also In re Tomlinson, 363 F.2d 928, 150 USPQ 623 (CCPA 1966) (The claim was directed to a process of inhibiting light degradation of polypropylene by mixing it with one of a genus of compounds, including nickel dithiocarbamate. A reference taught mixing polypropylene with nickel dithiocarbamate to lower heat degradation. The court held that the claims read on the obvious process of mixing polypropylene with the nickel dithiocarbamate and that the preamble of the claim was merely directed to the result of mixing the two materials. “While the references do not show a specific recognition of that result, its discovery by appellants is tantamount only to finding a property in the old composition.” 363 F.2d at 934, 150 USPQ at 628 (emphasis in original)).","provenance":{"source_file":"s2112.html","source_anchor":"d0e201429","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"kind":"narrative","host_section_id":"se_podrfx5d"},{"id":"cs_7wrfzhrp","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_7wrfzhrp","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Napier, 55 F.3d 610, 34 USPQ2d 1782 (Fed. Cir. 1995)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Napier","all_citations":["55 F.3d 610","34 USPQ2d 1782"],"canonical_citation":"In re Napier, 55 F.3d 610, 34 USPQ2d 1782 (Fed. Cir. 1995)","decision_year":1995,"court":"Fed. Cir."},{"id":"cs_c7byyf7l","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_c7byyf7l","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Grasselli, 713 F.2d 731, 218 USPQ 769 (Fed. Cir. 1983)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Grasselli","all_citations":["713 F.2d 731","218 USPQ 769"],"canonical_citation":"In re Grasselli, 713 F.2d 731, 218 USPQ 769 (Fed. Cir. 1983)","decision_year":1983,"court":"Fed. Cir."},{"id":"cs_4cnyhatg","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_4cnyhatg","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 51 USPQ2d 1943 (Fed. Cir. 1999)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Atlas Powder Co. v. IRECO Inc.","all_citations":["190 F.3d 1342","51 USPQ2d 1943"],"canonical_citation":"Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 51 USPQ2d 1943 (Fed. Cir. 1999)","decision_year":1999,"court":"Fed. Cir."},{"id":"cs_6lixyxgn","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_6lixyxgn","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Best","all_citations":["562 F.2d 1252","195 USPQ 430"],"canonical_citation":"In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977)","decision_year":1977,"court":"CCPA"},{"id":"cs_x275gh2h","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_x275gh2h","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Crish, 393 F.3d 1253, 73 USPQ2d 1364 (Fed. Cir. 2004)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Crish","all_citations":["393 F.3d 1253","73 USPQ2d 1364"],"canonical_citation":"In re Crish, 393 F.3d 1253, 73 USPQ2d 1364 (Fed. Cir. 2004)","decision_year":2004,"court":"Fed. Cir."},{"id":"cs_657jeyqc","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_657jeyqc","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 67 USPQ2d 1664 (Fed. Cir. 2003)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Schering Corp. v. Geneva Pharm. Inc.","all_citations":["339 F.3d 1373","67 USPQ2d 1664"],"canonical_citation":"Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 67 USPQ2d 1664 (Fed. Cir. 2003)","decision_year":2003,"court":"Fed. Cir."},{"id":"cs_ogqvtr33","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_ogqvtr33","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Toro Co. v. Deere & Co., 355 F.3d 1313, 69 USPQ2d 1584 (Fed. Cir. 2004)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Toro Co. v. Deere & Co.","all_citations":["355 F.3d 1313","69 USPQ2d 1584"],"canonical_citation":"Toro Co. v. Deere & Co., 355 F.3d 1313, 69 USPQ2d 1584 (Fed. Cir. 2004)","decision_year":2004,"court":"Fed. Cir."},{"id":"cs_5kbpau66","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_5kbpau66","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Abbott Labs v. Geneva Pharms., Inc., 182 F.3d 1315, 51 USPQ2d 1307 (Fed. Cir. 1999)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Abbott Labs v. Geneva Pharms., Inc.","all_citations":["182 F.3d 1315","51 USPQ2d 1307"],"canonical_citation":"Abbott Labs v. Geneva Pharms., Inc., 182 F.3d 1315, 51 USPQ2d 1307 (Fed. Cir. 1999)","decision_year":1999,"court":"Fed. Cir."},{"id":"cs_zog3lge5","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_zog3lge5","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 74 USPQ2d 1398 (Fed. Cir. 2005)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"SmithKline Beecham Corp. v. Apotex Corp.","all_citations":["403 F.3d 1331","74 USPQ2d 1398"],"canonical_citation":"SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 74 USPQ2d 1398 (Fed. Cir. 2005)","decision_year":2005,"court":"Fed. Cir."},{"id":"cs_gzlnth73","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_gzlnth73","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Omeprazole Patent Litigation, 483 F.3d 1364, 82 USPQ2d 1643 (Fed. Cir. 2007)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Omeprazole Patent Litigation","all_citations":["483 F.3d 1364","82 USPQ2d 1643"],"canonical_citation":"In re Omeprazole Patent Litigation, 483 F.3d 1364, 82 USPQ2d 1643 (Fed. Cir. 2007)","decision_year":2007,"court":"Fed. Cir."},{"id":"cs_hw2i7yo5","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_hw2i7yo5","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Rijckaert, 9 F.3d 1531, 28 USPQ2d 1955 (Fed. Cir. 1993)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Rijckaert","all_citations":["9 F.3d 1531","28 USPQ2d 1955"],"canonical_citation":"In re Rijckaert, 9 F.3d 1531, 28 USPQ2d 1955 (Fed. Cir. 1993)","decision_year":1993,"court":"Fed. Cir."},{"id":"cs_zap6baj4","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_zap6baj4","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Oelrich, 666 F.2d 578, 212 USPQ 323 (CCPA 1981)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Oelrich","all_citations":["666 F.2d 578","212 USPQ 323"],"canonical_citation":"In re Oelrich, 666 F.2d 578, 212 USPQ 323 (CCPA 1981)","decision_year":1981,"court":"CCPA"},{"id":"cs_4hagc4r5","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_4hagc4r5","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 71 USPQ2d 1081 (Fed. Cir. 2004)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Metabolite Labs., Inc. v. Lab.Corp. of Am. Holdings","all_citations":["370 F.3d 1354","71 USPQ2d 1081"],"canonical_citation":"Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 71 USPQ2d 1081 (Fed. Cir. 2004)","decision_year":2004,"court":"Fed. Cir."},{"id":"cs_fkbztcsb","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_fkbztcsb","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Ex parte Levy, 17 USPQ2d 1461 (Bd. Pat. App. & Inter. 1990)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Ex parte Levy","all_citations":["17 USPQ2d 1461"],"canonical_citation":"Ex parte Levy, 17 USPQ2d 1461 (Bd. Pat. App. & Inter. 1990)","decision_year":1990,"court":"BPAI"},{"id":"cs_jkcbynby","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_jkcbynby","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc., 773 F.3d 1186, 112 USPQ2d 1945 (Fed. Cir. 2014)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc.","all_citations":["773 F.3d 1186","112 USPQ2d 1945"],"canonical_citation":"PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc., 773 F.3d 1186, 112 USPQ2d 1945 (Fed. Cir. 2014)","decision_year":2014,"court":"Fed. Cir."},{"id":"cs_7ltofeni","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_7ltofeni","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Persion Pharms. LLC v. Alvogen Malta Operations LTD., 945 F.3d 1184, 2019 USPQ2d 494084 (Fed. Cir. 2019)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Persion Pharms. LLC v. Alvogen Malta Operations LTD.","all_citations":["945 F.3d 1184","2019 USPQ2d 494084"],"canonical_citation":"Persion Pharms. LLC v. Alvogen Malta Operations LTD., 945 F.3d 1184, 2019 USPQ2d 494084 (Fed. Cir. 2019)","decision_year":2019,"court":"Fed. Cir."},{"id":"cs_kbqe46rv","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_kbqe46rv","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 2020 USPQ2d 6227 (Fed. Cir. 2020)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Hospira, Inc. v. Fresenius Kabi USA, LLC","all_citations":["946 F.3d 1322","2020 USPQ2d 6227"],"canonical_citation":"Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 2020 USPQ2d 6227 (Fed. Cir. 2020)","decision_year":2020,"court":"Fed. Cir."},{"id":"cs_oqa5n4ei","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_oqa5n4ei","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Fitzgerald","all_citations":["619 F.2d 67","205 USPQ 594"],"canonical_citation":"In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980)","decision_year":1980,"court":"CCPA"},{"id":"cs_lur7s4dl","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_lur7s4dl","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Spada, 911 F.2d 705, 15 USPQ2d 1655 (Fed. Cir. 1990)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Spada","all_citations":["911 F.2d 705","15 USPQ2d 1655"],"canonical_citation":"In re Spada, 911 F.2d 705, 15 USPQ2d 1655 (Fed. Cir. 1990)","decision_year":1990,"court":"Fed. Cir."},{"id":"cs_miegnaib","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_miegnaib","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Titanium Metals Corp. v. Banner","all_citations":["778 F.2d 775","227 USPQ 773"],"canonical_citation":"Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985)","decision_year":1985,"court":"Fed. Cir."},{"id":"cs_yzmti7fq","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_yzmti7fq","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Ludtke","all_citations":["441 F.2d 660","169 USPQ 563"],"canonical_citation":"In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971)","decision_year":1971,"court":"CCPA"},{"id":"cs_37nixfgt","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_37nixfgt","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Northam Warren Corp. v. D. F. Newfield Co., 7 F.Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Northam Warren Corp. v. D. F. Newfield Co.","all_citations":["7 F.Supp. 773","22 USPQ 313"],"canonical_citation":"Northam Warren Corp. v. D. F. Newfield Co., 7 F.Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934)","decision_year":1934,"court":"E.D.N.Y."},{"id":"cs_szdc5gwo","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_szdc5gwo","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Ngai, 367 F.3d 1336, 70 USPQ2d 1862 (Fed. Cir. 2004)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Ngai","all_citations":["367 F.3d 1336","70 USPQ2d 1862"],"canonical_citation":"In re Ngai, 367 F.3d 1336, 70 USPQ2d 1862 (Fed. Cir. 2004)","decision_year":2004,"court":"Fed. Cir."},{"id":"cs_wwa2pmnq","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_wwa2pmnq","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Gulack, 703 F.2d 1381, 217 USPQ 401 (Fed. Cir. 1983)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Gulack","all_citations":["703 F.2d 1381","217 USPQ 401"],"canonical_citation":"In re Gulack, 703 F.2d 1381, 217 USPQ 401 (Fed. Cir. 1983)","decision_year":1983,"court":"Fed. Cir."},{"id":"cs_ffysa5hf","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_ffysa5hf","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Miller, 418 F.2d 1392 (CCPA 1969)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Miller","all_citations":["418 F.2d 1392"],"canonical_citation":"In re Miller, 418 F.2d 1392 (CCPA 1969)","decision_year":1969,"court":"CCPA"},{"id":"cs_4pz74nlc","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_4pz74nlc","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Seid, 161 F.2d 229, 73 USPQ 431 (CCPA 1947)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Seid","all_citations":["161 F.2d 229","73 USPQ 431"],"canonical_citation":"In re Seid, 161 F.2d 229, 73 USPQ 431 (CCPA 1947)","decision_year":1947,"court":"CCPA"},{"id":"cs_2xhflpyi","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_2xhflpyi","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Xiao, 462 Fed. App'x 947 (Fed. Cir. 2011)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Xiao","all_citations":["462 Fed. App'x 947"],"canonical_citation":"In re Xiao, 462 Fed. App'x 947 (Fed. Cir. 2011)","decision_year":2011,"court":"Fed. Cir."},{"id":"cs_ueejoi7w","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_ueejoi7w","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Bryan, 323 Fed. App'x 898 (Fed. Cir. 2009)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Bryan","all_citations":["323 Fed. App'x 898"],"canonical_citation":"In re Bryan, 323 Fed. App'x 898 (Fed. Cir. 2009)","decision_year":2009,"court":"Fed. Cir."},{"id":"cs_trwdxlol","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_trwdxlol","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 95 USPQ2d 1833 (2010)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"King Pharmaceuticals, Inc. v. Eon Labs, Inc.","all_citations":["616 F.3d 1267","95 USPQ2d 1833"],"canonical_citation":"King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 95 USPQ2d 1833 (2010)","decision_year":2010,"court":"Fed. Cir."},{"id":"cs_w5a4mgyw","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_w5a4mgyw","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Kao, 639 F.3d 1057, 98 USPQ2d 1799 (Fed. Cir. 2011)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Kao","all_citations":["639 F.3d 1057","98 USPQ2d 1799"],"canonical_citation":"In re Kao, 639 F.3d 1057, 98 USPQ2d 1799 (Fed. Cir. 2011)","decision_year":2011,"court":"Fed. Cir."},{"id":"cs_tw2nmt66","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_tw2nmt66","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 1986)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re King","all_citations":["801 F.2d 1324","231 USPQ 136"],"canonical_citation":"In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 1986)","decision_year":1986,"court":"Fed. Cir."},{"id":"cs_w4doqtmt","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_w4doqtmt","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"Ex parte Novitski, 26 USPQ2d 1389 (Bd. Pat. App. & Inter. 1993)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"Ex parte Novitski","all_citations":["26 USPQ2d 1389"],"canonical_citation":"Ex parte Novitski, 26 USPQ2d 1389 (Bd. Pat. App. & Inter. 1993)","decision_year":1993,"court":"BPAI"},{"id":"cs_njoybnpr","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_njoybnpr","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Hack, 245 F.2d 246, 114 USPQ 161 (CCPA 1957)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Hack","all_citations":["245 F.2d 246","114 USPQ 161"],"canonical_citation":"In re Hack, 245 F.2d 246, 114 USPQ 161 (CCPA 1957)","decision_year":1957,"court":"CCPA"},{"id":"cs_y4drnvwo","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_y4drnvwo","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re May, 574 F.2d 1082, 197 USPQ 601 (CCPA 1978)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re May","all_citations":["574 F.2d 1082","197 USPQ 601"],"canonical_citation":"In re May, 574 F.2d 1082, 197 USPQ 601 (CCPA 1978)","decision_year":1978,"court":"CCPA"},{"id":"cs_lbxayyp3","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/cs_lbxayyp3","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"case","rendered_text_html":"","rendered_text_plain":"In re Tomlinson, 363 F.2d 928, 150 USPQ 623 (CCPA 1966)","provenance":{"source_file":"s2112.html","source_anchor":"","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"short_name":"In re Tomlinson","all_citations":["363 F.2d 928","150 USPQ 623"],"canonical_citation":"In re Tomlinson, 363 F.2d 928, 150 USPQ 623 (CCPA 1966)","decision_year":1966,"court":"CCPA"},{"id":"se_wnxutwp2","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/se_wnxutwp2","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"section","rendered_text_html":"","rendered_text_plain":"","provenance":{"source_file":"s2112.html","source_anchor":"stub-2150","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"akn_urn":"/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2150","canonical_url":"https://mpep.io/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2150","section_number":"2150","chapter":"2100","depth":0,"title":"Section 2150","children_ids":[]},{"id":"se_zlugv67l","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/se_zlugv67l","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"section","rendered_text_html":"","rendered_text_plain":"","provenance":{"source_file":"s2112.html","source_anchor":"stub-2141","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"akn_urn":"/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2141","canonical_url":"https://mpep.io/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2141","section_number":"2141","chapter":"2100","depth":0,"title":"Section 2141","children_ids":[]},{"id":"se_m3gm7yow","corpus_id":"mpep-e9r01-2024-html","opaque_url":"https://mpep.io/n/se_m3gm7yow","effective_range":{"start_revision":"R-01.2024","end_revision":null},"node_type":"section","rendered_text_html":"","rendered_text_plain":"","provenance":{"source_file":"s2112.html","source_anchor":"stub-2113","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"},"akn_urn":"/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2113","canonical_url":"https://mpep.io/akn/us/statement/manual/uspto/2024/mpep/eng@2024-02-29!sec_2113","section_number":"2113","chapter":"2100","depth":0,"title":"Section 2113","children_ids":[]}],"edges":[{"id":"e_cvrl5xxt","edge_type":"cites-statute","source_id":"pb_ul55rwdp","target_id":"st_wrfmgtn5","properties":{"citation_text":"35 U.S.C. 102","specificity":"section","source_offset":{"start":125,"end":138}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_gviqz3jr","edge_type":"cites-statute","source_id":"pb_ul55rwdp","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":142,"end":145}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_6nzrjhca","edge_type":"cites-case","source_id":"pb_ul55rwdp","target_id":"cs_7wrfzhrp","properties":{"citation_text":"In re Napier, 55 F.3d 610, 613, 34 USPQ2d 1782, 1784 (Fed. Cir. 1995)","source_offset":{"start":277,"end":290},"pincite":"613","parenthetical":"affirmed a 35 U.S.C. 103 rejection based in part on inherent disclosure in one of the references","proposition":"inherent teaching is a question of fact in both anticipation and obviousness"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_2c3qr4yl","edge_type":"cites-statute","source_id":"pb_ul55rwdp","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":359,"end":372}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_epowpp3u","edge_type":"cites-case","source_id":"pb_ul55rwdp","target_id":"cs_c7byyf7l","properties":{"citation_text":"In re Grasselli, 713 F.2d 731, 739, 218 USPQ 769, 775 (Fed. Cir. 1983)","source_offset":{"start":456,"end":472},"pincite":"739","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201044","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_moxsycue","edge_type":"cites-case","source_id":"pb_hbehwp7b","target_id":"cs_4cnyhatg","properties":{"citation_text":"Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999)","source_offset":{"start":219,"end":250},"pincite":"1347","proposition":"discovering an unappreciated property of old composition does not make it patentably new"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_bsxwrz4y","edge_type":"cites-case","source_id":"pb_hbehwp7b","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977)","source_offset":{"start":469,"end":480},"pincite":"1254"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_kydtaoux","edge_type":"cites-case","source_id":"pb_hbehwp7b","target_id":"cs_x275gh2h","properties":{"citation_text":"In re Crish, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004)","source_offset":{"start":536,"end":548},"pincite":"1258","proposition":"sequencing a known plasmid does not make its inherent DNA sequence novel"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_hobvjagu","edge_type":"cross-references","source_id":"pb_hbehwp7b","target_id":"se_7hgbpjeu","properties":{"link_text":"MPEP 2112.01","target_anchor":"d0e201273"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_mq3rymu6","edge_type":"cross-references","source_id":"pb_hbehwp7b","target_id":"se_zlugv67l","properties":{"link_text":"MPEP § 2141.02","target_anchor":"d0e209106"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_gcw65xpb","edge_type":"cites-statute","source_id":"pb_hbehwp7b","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":1205,"end":1218}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201066","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_aaz6hc6b","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_657jeyqc","properties":{"citation_text":"Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003)","source_offset":{"start":216,"end":253},"pincite":"1377","parenthetical":"rejecting the contention that inherent anticipation requires recognition by a person of ordinary skill in the art before the critical date and allowing expert testimony with respect to post-critical date clinical trials to show inherency","proposition":"inherent feature need not be recognized at the relevant time"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_xeu6qki7","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_ogqvtr33","properties":{"citation_text":"Toro Co. v. Deere & Co., 355 F.3d 1313, 1320, 69 USPQ2d 1584, 1590 (Fed. Cir. 2004)","source_offset":{"start":563,"end":587},"pincite":"1320","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ca66yg2l","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_5kbpau66","properties":{"citation_text":"Abbott Labs v. Geneva Pharms., Inc., 182 F.3d 1315, 1319, 51 USPQ2d 1307, 1310 (Fed. Cir. 1999)","source_offset":{"start":899,"end":935},"pincite":"1319"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_tftt6aov","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_4cnyhatg","properties":{"citation_text":"Atlas Powder Co. v. IRECO, Inc., 190 F.3d 1342, 1348-49, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999)","source_offset":{"start":1241,"end":1273},"pincite":"1348-49"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_bspegblk","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_zog3lge5","properties":{"citation_text":"SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1343-44, 74 USPQ2d 1398, 1406-07 (Fed. Cir. 2005)","source_offset":{"start":1568,"end":1609},"pincite":"1343-44"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_6dmz7rpb","edge_type":"cites-case","source_id":"pb_zo6lucba","target_id":"cs_gzlnth73","properties":{"citation_text":"In re Omeprazole Patent Litigation, 483 F.3d 1364, 1373, 82 USPQ2d 1643, 1650 (Fed. Cir. 2007)","source_offset":{"start":2042,"end":2077},"pincite":"1373"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201101","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_5lx3ulhd","edge_type":"cites-statute","source_id":"pb_4xu2oes4","target_id":"st_wrfmgtn5","properties":{"citation_text":"35 U.S.C. 102","specificity":"section","source_offset":{"start":266,"end":279}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201130","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_53bwz6xa","edge_type":"cites-statute","source_id":"pb_4xu2oes4","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":367,"end":380}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201130","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_lvbckujb","edge_type":"cites-case","source_id":"pb_4xu2oes4","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977)","source_offset":{"start":424,"end":435},"pincite":"1255"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201130","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_hbe67lso","edge_type":"cites-case","source_id":"pb_qz3ymp3z","target_id":"cs_hw2i7yo5","properties":{"citation_text":"In re Rijckaert, 9 F.3d 1531, 1534, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993)","source_offset":{"start":169,"end":185},"pincite":"1534","parenthetical":"reversed rejection because inherency was based on what would result due to optimization of conditions, not what was necessarily present in the prior art"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201164","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ctwvfrao","edge_type":"cites-case","source_id":"pb_qz3ymp3z","target_id":"cs_zap6baj4","properties":{"citation_text":"In re Oelrich, 666 F.2d 578, 581-82, 212 USPQ 323, 326 (CCPA 1981)","source_offset":{"start":399,"end":413},"pincite":"581-82"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201164","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_oaw6rasu","edge_type":"cites-case","source_id":"pb_qz3ymp3z","target_id":"cs_4hagc4r5","properties":{"citation_text":"Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1367, 71 USPQ2d 1081, 1091 (Fed. Cir. 2004)","source_offset":{"start":649,"end":679},"pincite":"1367","proposition":"an invitation to investigate a genus is not an inherent disclosure of all species"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201164","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_e7brv33z","edge_type":"cites-case","source_id":"pb_ohiigq4r","target_id":"cs_fkbztcsb","properties":{"citation_text":"Ex parte Levy, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990)","source_offset":{"start":258,"end":271},"pincite":"1464","parenthetical":"emphasis in original","proposition":"examiner must provide fact basis or technical reasoning that the inherent characteristic necessarily flows"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201188","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_2au4j7ee","edge_type":"cites-case","source_id":"pb_ohiigq4r","target_id":"cs_jkcbynby","properties":{"citation_text":"PAR Pharmaceutical, Inc. v. TWI Pharmaceuticals, Inc., 773 F.3d 1186, 112 USPQ2d 1945 (Fed. Cir. 2014)","source_offset":{"start":351,"end":405},"proposition":"use of inherency must be carefully circumscribed in the obviousness context"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201188","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ul2jphkd","edge_type":"cites-case","source_id":"pb_ohiigq4r","target_id":"cs_7ltofeni","properties":{"citation_text":"Persion Pharms. LLC v. Alvogen Malta Operations LTD., 945 F.3d 1184, 1191, 2019 USPQ2d 494084 (Fed. Cir. 2019)","source_offset":{"start":1350,"end":1403},"pincite":"1191","signal":"but_see","proposition":"inherency may meet a missing limitation as the natural result of a combination of references"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201188","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_xuyeggds","edge_type":"cites-case","source_id":"pb_ohiigq4r","target_id":"cs_kbqe46rv","properties":{"citation_text":"Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 1329-32, 2020 USPQ2d 6227 (Fed. Cir. 2020)","source_offset":{"start":1975,"end":2016},"pincite":"1329-32","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201188","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_cf2shbur","edge_type":"cites-case","source_id":"pb_hfcu5s4r","target_id":"cs_bcvvwgih","properties":{"citation_text":"In re Schreiber, 128 F.3d 1473, 44 USPQ2d 1429 (Fed. Cir. 1997)","source_offset":{"start":3,"end":19},"proposition":"prior art spout inherently performed the dispensing function recited in applicant's claim"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201203","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_hgrsrabj","edge_type":"cites-case","source_id":"pb_nvvyx6qy","target_id":"cs_bcvvwgih","properties":{"citation_text":"In re Schreiber, 128 F.3d 1473, 1478, 44 USPQ2d 1429, 1432 (Fed. Cir. 1997)","source_offset":{"start":0,"end":10},"pincite":"1478"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201213","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_w7dxnnzi","edge_type":"quotes-from","source_id":"nq_l2pbudhk","target_id":"cs_bcvvwgih","properties":{"quoted_text":"[N]othing in Schreiber’s [applicant’s] claim suggests that Schreiber’s container is 'of a different shape’ than Harz’s [patent]. In fact, [ ] an embodiment according to Harz (Fig. 5) and the embodiment depicted in figure 1 of Schreiber’s application have the same general shape. For that reason, the examiner was justified in concluding that the opening of a conically shaped top as disclosed by Harz is inherently of a size sufficient to ‘allow [ ] several kernels of popped popcorn to pass through at the same time’ and that the taper of Harz’s conically shaped top is inherently of such a shape ‘as to by itself jam up the popped popcorn before the end of the cone and permit the dispensing of only a few kernels at a shake of a package when the top is mounted to the container.’ The examiner therefore correctly found that Harz established a prima facie case of anticipation.","quoted_text_sha256":"120d550f4378fc59ac8c4305cc1be2b1014fb7c948a3cfae9d9d42406c8839a8","source_offset":{"start":0,"end":879},"pincite":"1478"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201209","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_vbf75noi","edge_type":"cites-statute","source_id":"pb_kukynnj6","target_id":"st_wrfmgtn5","properties":{"citation_text":"35 U.S.C. 102","specificity":"section","source_offset":{"start":219,"end":232}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201222","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_c3ptt7nn","edge_type":"cites-statute","source_id":"pb_kukynnj6","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":269,"end":282}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201222","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_tgqxu4q3","edge_type":"cites-case","source_id":"pb_kukynnj6","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977)","source_offset":{"start":344,"end":356},"pincite":"1255","parenthetical":"footnote and citation omitted","proposition":"PTO may shift burden to applicant to prove prior art does not inherently possess the claimed characteristics"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201222","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ccjddnrf","edge_type":"cites-case","source_id":"pb_kukynnj6","target_id":"cs_oqa5n4ei","properties":{"citation_text":"In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980)","source_offset":{"start":534,"end":552},"pincite":"70"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201222","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_5wgfn4lv","edge_type":"cites-case","source_id":"pb_3imzasht","target_id":"cs_oqa5n4ei","properties":{"citation_text":"In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980)","source_offset":{"start":3,"end":14}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201240","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_2y5m4qw5","edge_type":"cites-statute","source_id":"pb_3imzasht","target_id":"st_wrfmgtn5","properties":{"citation_text":"35 U.S.C. 102","specificity":"section","source_offset":{"start":1794,"end":1807}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201240","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_jykkuhak","edge_type":"cites-case","source_id":"pb_5rqxbgj7","target_id":"cs_bcvvwgih","properties":{"citation_text":"In re Schreiber, 128 F.3d 1473, 1478, 44 USPQ2d 1429, 1432 (Fed. Cir. 1997)","source_offset":{"start":3,"end":13},"pincite":"1478"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201258","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ilkcerh7","edge_type":"cross-references","source_id":"pb_sbbzbov5","target_id":"se_m3gm7yow","properties":{"link_text":"MPEP § 2113","target_anchor":"d0e201450"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201267","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_pmgtxepp","edge_type":"cross-references","source_id":"pb_2obgxbj4","target_id":"se_wnxutwp2","properties":{"link_text":"MPEP § 2150","target_anchor":"ch2100_d2002f_22805_16e"},"provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d223b3_23296_39d","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_m63k7u45","edge_type":"cites-case","source_id":"pb_yj3sbauc","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)","source_offset":{"start":257,"end":307},"pincite":"1255","proposition":"identical/substantially identical products establish a prima facie case of anticipation or obviousness"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201281","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_kqw6bwf3","edge_type":"cites-case","source_id":"pb_yj3sbauc","target_id":"cs_lur7s4dl","properties":{"citation_text":"In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990)","source_offset":{"start":496,"end":508},"pincite":"709"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201281","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_tsgre6ld","edge_type":"cites-case","source_id":"pb_yj3sbauc","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)","source_offset":{"start":734,"end":762},"pincite":"1255"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201281","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_mjbrdxra","edge_type":"cites-case","source_id":"pb_yj3sbauc","target_id":"cs_miegnaib","properties":{"citation_text":"Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985)","source_offset":{"start":790,"end":811},"signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201281","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_stw6v4fm","edge_type":"cites-case","source_id":"pb_5gnvmizp","target_id":"cs_yzmti7fq","properties":{"citation_text":"In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971)","source_offset":{"start":9,"end":22},"signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201308","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_uxjaklvh","edge_type":"cites-case","source_id":"pb_5gnvmizp","target_id":"cs_37nixfgt","properties":{"citation_text":"Northam Warren Corp. v. D. F. Newfield Co., 7 F.Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934)","source_offset":{"start":742,"end":762}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201308","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_4gxrucfg","edge_type":"cites-case","source_id":"pb_zjsijpps","target_id":"cs_lur7s4dl","properties":{"citation_text":"In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990)","source_offset":{"start":89,"end":101},"pincite":"709","proposition":"products of identical chemical composition cannot have mutually exclusive properties"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201330","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_6337ibi5","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_szdc5gwo","properties":{"citation_text":"In re Ngai, 367 F.3d 1336, 1339, 70 USPQ2d 1862, 1864 (Fed. Cir. 2004)","source_offset":{"start":238,"end":249},"pincite":"1339","parenthetical":"anticipated by a kit teaching instructions and a buffer agent even though the content of the instructions differed","proposition":"nonfunctional printed matter does not distinguish an otherwise identical product"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_x26fl2et","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_wwa2pmnq","properties":{"citation_text":"In re Gulack, 703 F.2d 1381, 1385-86, 217 USPQ 401, 404 (Fed. Cir. 1983)","source_offset":{"start":766,"end":779},"pincite":"1385-86","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_ewp27xio","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_ffysa5hf","properties":{"citation_text":"In re Miller, 418 F.2d 1392, 1396 (CCPA 1969)","source_offset":{"start":1157,"end":1170},"pincite":"1396"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_22xoejug","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_4pz74nlc","properties":{"citation_text":"In re Seid, 161 F.2d 229, 73 USPQ 431 (CCPA 1947)","source_offset":{"start":1315,"end":1326}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_5wwpr6x6","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_2xhflpyi","properties":{"citation_text":"In re Xiao, 462 Fed. App'x 947, 950-51 (Fed. Cir. 2011)","source_offset":{"start":1530,"end":1541},"pincite":"950-51"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_rrt6uep5","edge_type":"cites-case","source_id":"pb_tlhvxuyc","target_id":"cs_ueejoi7w","properties":{"citation_text":"In re Bryan, 323 Fed. App'x 898, 901 (Fed. Cir. 2009)","source_offset":{"start":1773,"end":1785},"pincite":"901"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201343","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_4zx3wbaw","edge_type":"cites-case","source_id":"pb_kxzigdpz","target_id":"cs_trwdxlol","properties":{"citation_text":"King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1279, 95 USPQ2d 1833, 1842 (2010)","source_offset":{"start":333,"end":372},"pincite":"1279","proposition":"printed-matter rationale extends to instruction limitations added to known methods"},"provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d24d26_27ff5_327","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_e5j2atvh","edge_type":"cites-case","source_id":"pb_kxzigdpz","target_id":"cs_szdc5gwo","properties":{"citation_text":"In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004)","source_offset":{"start":1311,"end":1322},"pincite":"1339"},"provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d24d26_27ff5_327","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_wrq5nvxz","edge_type":"cites-case","source_id":"pb_kxzigdpz","target_id":"cs_w5a4mgyw","properties":{"citation_text":"In re Kao, 639 F.3d 1057, 1072-73, 98 USPQ2d 1799, 1811-12 (Fed. Cir. 2011)","source_offset":{"start":1371,"end":1381},"pincite":"1072-73","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"ch2100_d24d26_27ff5_327","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_l52efanm","edge_type":"cites-case","source_id":"pb_2nihdymr","target_id":"cs_tw2nmt66","properties":{"citation_text":"In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 1986)","source_offset":{"start":417,"end":428},"proposition":"prior art device anticipates a claimed process if it carries out the process in normal operation"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_rsdlatm7","edge_type":"cites-statute","source_id":"pb_2nihdymr","target_id":"st_wrfmgtn5","properties":{"citation_text":"35 U.S.C. 102","specificity":"section","source_offset":{"start":2028,"end":2041}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_akdy2vjj","edge_type":"cites-statute","source_id":"pb_2nihdymr","target_id":"st_ompe7akv","properties":{"citation_text":"35 U.S.C. 103","specificity":"section","source_offset":{"start":2518,"end":2531}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_qgrfy3zb","edge_type":"cites-case","source_id":"pb_2nihdymr","target_id":"cs_6lixyxgn","properties":{"citation_text":"In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)","source_offset":{"start":1467,"end":1478},"pincite":"1255","signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_twvct4ul","edge_type":"cites-case","source_id":"pb_2nihdymr","target_id":"cs_w4doqtmt","properties":{"citation_text":"Ex parte Novitski, 26 USPQ2d 1389 (Bd. Pat. App. & Inter. 1993)","source_offset":{"start":2535,"end":2543}},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201368","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_6ipuvijg","edge_type":"cites-case","source_id":"pb_y34bvfxf","target_id":"cs_njoybnpr","properties":{"citation_text":"In re Hack, 245 F.2d 246, 248, 114 USPQ 161, 163 (CCPA 1957)","source_offset":{"start":154,"end":165},"pincite":"248"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201429","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_xjdpa5ws","edge_type":"cites-case","source_id":"pb_y34bvfxf","target_id":"cs_y4drnvwo","properties":{"citation_text":"In re May, 574 F.2d 1082, 1090, 197 USPQ 601, 607 (CCPA 1978)","source_offset":{"start":401,"end":410},"pincite":"1090","proposition":"claiming an old composition's use directed to its result or property is anticipated"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201429","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}},{"id":"e_heki5r62","edge_type":"cites-case","source_id":"pb_y34bvfxf","target_id":"cs_lbxayyp3","properties":{"citation_text":"In re Tomlinson, 363 F.2d 928, 150 USPQ 623 (CCPA 1966)","source_offset":{"start":1153,"end":1169},"signal":"see_also"},"provenance":{"source_file":"s2112.html","source_anchor":"d0e201429","source_sha256":"d42fe81e7f500499076fc68e3f0f9eda953fe72f039988f9b22fe11a94a986da"}}]}}